Related Experiment Videos
Flecainide
Insights
Flecainide, a Class IC antiarrhythmic, effectively treats supraventricular arrhythmias due to its low side effect profile. However, concerns about proarrhythmia limit its use in ventricular arrhythmias, especially post-myocardial infarction.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Flecainide is a Class IC antiarrhythmic drug.
- It primarily slows cardiac conduction.
- Class IC agents are known for potential proarrhythmic effects.
Purpose of the Study:
- To review the electrophysiologic effects of flecainide.
- To evaluate its efficacy and safety in various arrhythmias.
- To understand its role in clinical practice.
Main Methods:
- Review of flecainide's electrophysiologic properties.
- Analysis of clinical trial data, including the CAST trial.
- Assessment of efficacy in supraventricular and ventricular arrhythmias.
Main Results:
- Flecainide effectively suppresses premature ventricular contractions and nonsustained ventricular arrhythmias.
- Its efficacy is modest when electrophysiologic testing is the endpoint.
- The CAST trial indicated a risk of proarrhythmia, particularly in post-myocardial infarction patients.
- Flecainide has a low noncardiac side effect profile.
Conclusions:
- Flecainide is effective for supraventricular arrhythmias due to its favorable side effect profile.
- Concerns regarding proarrhythmia have reduced its use for ventricular arrhythmias, especially in high-risk patients.
- Careful patient selection is crucial for flecainide therapy.
Abstract:
Flecainide is a Class IC antiarrhythmic agent whose primary electrophysiologic effect is a slowing of conduction in a wide range of cardiac tissues. It is well absorbed and effective in suppressing isolated premature ventricular contractions (PVCs) or nonsustained ventricular arrhythmia but has only a modest efficacy when electrophysiologic testing is used as an endpoint. Its adverse effect on mortality in the CAST trial suggested a propensity to proarrhythmia--a phenomenon to which the Class IC agents appear particularly prone. Despite the applicability of the CAST study only to patients with a prior myocardial infarction, there has been a shift away from flecainide in ventricular arrhythmia, but the low noncardiac side effect profile of the agent allows for its continued use in a wide variety of supraventricular arrhythmias.